Ghazy Sarah, Rashed Mohammed E, Ali Amal E, Zedan Hamdallah H
Bacterial Lab, Central Administration of Biological and Innovative Products and Clinical Studies, Egyptian Drug Authority, Giza, Egypt.
Lab Evaluation Administration, Central Administration of Biological and Innovative Products and Clinical Studies, Egyptian Drug Authority, Giza, Egypt.
Clin Exp Vaccine Res. 2025 Apr;14(2):138-148. doi: 10.7774/cevr.2025.14.e15. Epub 2025 Mar 25.
Effective treatment for animal bites is essential, encompassing immediate measures and protocols for rabies and tetanus vaccination. In this study, we evaluated the effectiveness of the administration of individual and combined rabies-tetanus (RT) vaccines in mice as model animals.
Animal groups were injected with either undiluted Toxovac combined with Rabies vaccine (RT/Group 1)/Speeda (ST/Group 3), 2-fold diluted Toxovac with Rabies vaccine (RT1/2/Group 2), or purified tetanus toxoid with Speeda (Spurf/Group 4). Mice were immunized with either 2 intraperitoneal (IP) doses at one-week interval or one subcutaneous (SC) dose for rabies immunogenicity, and with one SC dose for tetanus immunogenicity. The potency of the vaccines was determined through challenge test, while their immunogenicity was examined by measuring the anti-rabies and anti-tetanus immunoglobulin G response.
All tested vaccines were potent except Spurf; tetanus was not potent. Rabies' immunogenicity for all combinations through both routes of administration showed comparable antibody response & non-significant difference (p≥0.05) at days 14 and 28 compared to single rabies injected by 2 IP doses. Tetanus' immunogenicity in combinations was compared with Toxovac. RT depicted higher antibody response on both days 14 and 28. Whereas RT1/2 showed a non-significant difference on both days 14 and 28. Therefore, rabies has a synergistic effect on tetanus in combination.
The immune response to rabies in combination vaccine injected as a single SC dose was as effective as 2 IP doses of single vaccine. Our results highlight the potential of RT combination vaccine via SC as a cost-effective means to provide protective immunity.
动物咬伤的有效治疗至关重要,包括狂犬病和破伤风疫苗接种的即时措施及方案。在本研究中,我们评估了狂犬病 - 破伤风(RT)联合疫苗和单独疫苗在作为模型动物的小鼠中的接种效果。
将动物分组,分别注射未稀释的Toxovac与狂犬病疫苗组合(RT/第1组)/Speeda(ST/第3组)、2倍稀释的Toxovac与狂犬病疫苗组合(RT1/2/第2组),或纯化破伤风类毒素与Speeda组合(Spurf/第4组)。小鼠通过间隔一周腹腔注射(IP)两剂或皮下注射(SC)一剂进行狂犬病免疫原性接种,并通过皮下注射一剂进行破伤风免疫原性接种。通过攻毒试验确定疫苗效力,通过测量抗狂犬病和抗破伤风免疫球蛋白G反应检测其免疫原性。
除Spurf外,所有测试疫苗均有效;破伤风疫苗无效。与通过腹腔注射两剂的单一狂犬病疫苗相比,所有组合通过两种给药途径在第14天和第28天的狂犬病免疫原性均显示出相当的抗体反应且无显著差异(p≥0.05)。将组合疫苗中破伤风的免疫原性与Toxovac进行比较。RT在第14天和第28天均显示出更高的抗体反应。而RT1/2在第14天和第28天均显示无显著差异。因此,狂犬病在联合疫苗中对破伤风有协同作用。
单次皮下注射联合疫苗对狂犬病的免疫反应与两剂腹腔注射单一疫苗一样有效。我们的结果突出了通过皮下注射RT联合疫苗作为提供保护性免疫的一种经济有效的手段的潜力。